Responses
Regular and young investigator award abstracts
Clinical trials completed
265 Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort
Compose a Response to This Article
Other responses
No responses have been published for this article.
